All News
Poets Know It (3.13.2026)
Dr. Jack Cush reviews the news, regulatory decisions and new journal articles.
Read Article
Rheumatic Immune-related Adverse Effects with Checkpoint Inhibitor Therapy
A retrospective study of patients who developed rheumatic immune-related adverse events (R-irAEs) after receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain suggests that early recognition can lead to effective management that allows continuation of cancer therapy.
Read Article
Managing Gout in CKD Patients
A current review article addressed the management of gout patients with chronic kidney disease (CKD). This full read review addresses the epidemiology, challenges, treatment decisions and outcomes.
Read Article
b/ts-DMARDs Do Not Arrest Bone Loss in RA
In RA, the goal is to control or arrest inflammation such that articular and bony damage is halted. While we have many effective therapies, it is not clear that biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis outcomes in RA. A current real-world study showed that 1 year of b/tsDMARDs use did not arrest osteoporosis progression.
Read Article
“We’re facing a tsunami of retiring older, white rheumatologists” – Chad Deal, MD
Dr. John Cush RheumNow ( View Tweet)
UCB announced topline results of the BE-BOLD head-to-head study where bimekizumab (IL-17i) was superior to risankizumab (IL-23i) study; 553 active PsA in achieving an ACR50 response at 16 weeks. Enrolled PsA pts were either bilogic naïve or who had previous exposure to 1 TNFi
Dr. John Cush RheumNow ( View Tweet)
https://t.co/4UQlqwujiR 2026 — On Demand
Catch the sessions everyone in rheumatology is talking about:
• RA advances
• Psoriatic arthritis decisions
• Spondyloarthritis updates
• Autoimmune disease highlights
• Vasculitis insights
Full recordings + slides available now. https://t.co/QT6NOXakVv
Links:
Dr. John Cush RheumNow ( View Tweet)
Annual fibromyalgia survey (FIRST) in axSpA pts in the DESIR cohort. FM was found in 22% (& assoc w/ less HLA-B27+ & XRay sacroiliitis, equal MRI SI a& ^ CRP. FM/AxSpA had less self-reported Dz activity, QOL, more disability & more likely to Rx w/ TNFi (64% vs 41%), but resp https://t.co/9rkZFUSB2M
Dr. John Cush RheumNow ( View Tweet)
The Role of Calcineurin Inhibitors in Lupus Nephritis
In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus (SLE), contributing significantly to the morbidity and mortality of the affected individuals (1). However, significant https://t.co/sc4cgAYzGy
Dr. John Cush RheumNow ( View Tweet)
Rheumatic Immune-related Adverse Effects with Checkpoint Inhibitor Therapy
A retrospective study of patients who developed rheumatic immune-related adverse events (R-irAEs) after receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain suggests that early https://t.co/jKCbIvfebm
Dr. John Cush RheumNow ( View Tweet)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower serum uric acid levels, by approximately 0.6 to 1.5 mg/dL. They increase renal uric acid excretion via a uricosuric effect), thereby reducing gout risk by 30% to 50%. https://t.co/weXVOhpiP9 https://t.co/NsCRNi9JI9
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of calcineurin inhib. in RA - 11 RCTs, 1793 RA pts. Cyclosporin (CSA( (RR 1.6 & Tacrolimus (TAC (RR 2.1) signif improved ACR20 responses. CSA was dose dependent, less so w/ TAC. Both require serum Creat. monitoring consistent increase in s-Cr https://t.co/OxNGYbupnt https://t.co/F08vDCMYtr
Links:
Dr. John Cush RheumNow ( View Tweet)
2 RCTs of 699 children Tx in ER for acute limb injury compared 1 dose of oral acetaminophen or hydromorphone to ibuprofen - none significantly reduce self-reported pain scores at 60 minutes. Use of hydromorphone resulted in a 4-fold increase in adverse events. https://t.co/cqddDES9V0
Dr. John Cush RheumNow ( View Tweet)
American Academy of Physician Associates is determined to change PA to mean 'physician associate' in USA. Maine, New Hampshire, Oregon have adopted it, but the AMA is opposed. This has become a legislative, financial and legal issue. https://t.co/u0tejo0lvn https://t.co/1VEbwpqlN8
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus
A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis.
https://t.co/b5qHBotxbI https://t.co/dqzZodOokq
Dr. John Cush RheumNow ( View Tweet)
Data from the KEEPsAKE 1 trial in bio-naive patients with PsA Dr. Wells and Dr. Singla share 5-year safety and efficacy data of an IL–23 inhibitor and their thoughts on using it to manage PsA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/xoPdYAof7m https://t.co/ycqMod2qLN
Dr. John Cush RheumNow ( View Tweet)
Prebiotic fibre improves knee OA. Study of 117 older adults w/ KOA Rx w/ 6wks of inulin (fibre) or Physiotherapy exercise (PSE) or both vs PBO. Both Inulin & PSE signif improved pain & PSE vs PBO ( −1.11 to -2.5; p <0.045); inulin also improved pain sensitivity & grip strength https://t.co/Efic4mru1i
Dr. John Cush RheumNow ( View Tweet)
Long-Term Hydroxychloroquine Retinopathy Risk
About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.
https://t.co/Gp6o0FfEYA https://t.co/TjLNXl229v
Dr. John Cush RheumNow ( View Tweet)
AI model was superior in diagnosing Acromegaly from dorsal hand photographs - w. sensitivity 0.89, specificity 0.91, PPV 0.88, NPV 0.93, F1-score of 0.89, AUC 0.96, outperforming specialists, Study of 716 pts (317 acromegaly; 399 controls) & 11480 images, from 15 Japanese https://t.co/8RM4wf8vGi
Dr. John Cush RheumNow ( View Tweet)
Basic, full-read overview of "JAK inhibitors: risks and safety principles" from the Pharmaceutical Journal. Addresses MOA, indications, warnings, monitoring, adverse effects, interactions, Serious AEs, vaccination and best practices. https://t.co/qrqeu1CzRg https://t.co/7qIszLwUrf
Dr. John Cush RheumNow ( View Tweet)
